China’s New Guidelines On Foreign Investment Loosens Restrictions On Drug Distribution
This article was originally published in The Pink Sheet Daily
Executive Summary
A revised investment rule could open new opportunities in China’s enormous pharmaceutical distribution business. The sector, which has already embraced U.S. giant Cardinal Health and the UK’s Alliance Boots, is set for a major consolidation in coming years.
You may also be interested in...
China's Top Drug Distributors Are Soaring: China Earnings Round Up (Part 2)
SHANGHAI - China's drug distribution market and retail pharmacy revenue reached RMB 708 billion ($110.9 billion) in 2010, a 24.6% increase from 2009, and the top three drug distributors' market share increased by 5.8% to 26.7% through aggressive acquisitions to expand their distribution networks, according to China's Ministry of Commerce.
Alliance Boots Taps Retired Zuellig Pharma CEO to Lead Asia Operation, With M&A On The Mind
Major UK pharmaceutical and beauty products distributor Alliance Boots announced the appointment of retired Zuellig Pharma CEO Fritz Horlacher to head its heathcare division in Asia. The company aims to expand in Asia, especially in Thailand and Korea, which will pose a big challenge to Zuellig and other heavyweight pharmaceutical distributors
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports